US FDA approves PTC Therapeutics' metabolic disorder drug

BioMarin Pharmaceutical

28/07/2025 21:23

July 28 (Reuters) - The U.S. Food and Drug Administration has approved PTC Therapeutics' PTCT.O oral drug to treat a rare inherited metabolic disorder that prevents the body from properly breaking down certain amino acids, the company said on Monday.

 (Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Alan Barona)

 ((Kamal.Choudhury@thomsonreuters.com))